Меню
Идёт набор NCT05700279

Preventing the Development of Chronic Pain: Treating PTSD at Acute Pain Onset

Без фазы С лечением PTSD Chronic Pain

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Stellate Ganglion Block, Cognitive Processing Therapy.
Кому может быть актуально
Состояния в реестре: PTSD, Chronic Pain. Базовые параметры: 18 лет — 70 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Обзор

Although most people recover from acute pain (such as pain caused by injury, surgery, repetitive motion, or unknown causes), many people do not fully recover and will experience chronic pain. Untreated posttraumatic stress disorder (PTSD) appears to be a key risk factor for the transition from acute pain to chronic pain. However, few published studies have addressed the issue of preventing the transition from acute to chronic pain via PTSD reduction. This project will aim to test whether trauma-related PTSD symptoms can be reduced using either Stellate Ganglion Block (SGB) treatment or Cognitive Processing Therapy (CPT), and whether reducing PTSD symptoms can prevent the transition from non-injury based acute pain to chronic pain.

Подробное описание

Untreated PTSD appears to be a key risk factor for the transition from acute pain to chronic pain. Thus, reducing PTSD symptoms during an acute pain episode may potentially decrease the likelihood of transitioning to chronic pain. CPT is an evidence-based trauma-focused cognitive behavioral treatment that is hypothesized to reduce PTSD symptoms via reducing negative trauma-related cognitions about oneself, others, and the world. SGB treatment is an injection of a local anesthetic into the stellate ganglion, which is a bundle of nerves located at the base of the neck that is part of the sympathetic nervous system. Previous studies suggest that 1-week massed CPT and SGB treatment can both reduce the severity of PTSD symptoms in short periods of time via two distinct psychological and biological mechanisms.

This 4 year project will test study hypotheses in a sample of 345 individuals with PTSD symptoms who present to the presenting to the Rush University Medical Center ED or Rush's Primary Care and Preventive Medicine group with non-injury based acute pain. Participants will be randomly assigned to receive 1-week massed CPT, 2 SGB treatments, or usual care. All participants will complete identical self-report and/or clinician administered assessments at baseline (prior to randomization) and on study days 1, 7, 14, 21, 28, 56 (approximately 3 months after the initial ED presentation or Presentation to Preventive Medicine), and 112 (approximately 6 months after ED presentation or presentation to Preventive Medicine).

Вмешательства

  • Процедура Stellate Ganglion Block
    Stellate Ganglion Block (SGB) procedure involves an injection of a local anesthetic (0.5% ropivacaine) around the stellate ganglion (a bundle of nerves located at the base of the neck) to block the transmission of pain signals. The SGB injection is administered by an anesthesiologist.
  • Поведенческое Cognitive Processing Therapy
    Cognitive Processing Therapy (CPT) is a form of trauma-based talk therapy that will be conducted by clinical therapists. CPT can help people identify and challenge unhelpful trauma-related beliefs about themselves, others, and the world.

Первичные конечные точки

  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity [Срок оценки: Through study completion, for an average of 6 months]
  • Change in PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (PCL-5) Self-Reported PTSD Symptoms [Срок оценки: Through study completion, for an average of 6 months]
Вторичные конечные точки (9)
  • Change in SCID-5 mood and anxiety disorder diagnoses [Срок оценки: Through study completion, for an average of 6 months]
  • Change in AUDIT-C Self-Reported Substance Use [Срок оценки: Through study completion, for an average of 6 months]
  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference [Срок оценки: Through study completion, for an average of 6 months]
  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Depression (Short Form) [Срок оценки: Through study completion, for an average of 6 months]
  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function (Short Form) [Срок оценки: Through study completion, for an average of 6 months]
  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance (short form) [Срок оценки: Through study completion, for an average of 6 months]
  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety (short form) [Срок оценки: Through study completion, for an average of 6 months]
  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS) anger (short form) [Срок оценки: Through study completion, for an average of 6 months]
  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Satisfaction with Social Roles [Срок оценки: Through study completion, for an average of 6 months]

Критерии участия

Критерии включения

  • Age 18 to 70 years
  • Ability to read and write English sufficiently to understand and complete study questionnaires and participate in interviews
  • Presenting to the Rush ED with acute pain without debilitating trauma
  • A primary acute pain site
  • Self-reported symptoms consistent with a diagnosis of PTSD
  • People with well-controlled diabetes or HIV/AIDS with chronic neuropathic pain will be included if their acute pain complaint at ED presentation is not due to neuropathic pain
  • Individuals with a history of psychotic or bipolar disorder that is currently well managed, have been treated for the condition for at least 3 months, are able to coherently answer interview questions, and are judged by study staff to be capable of participating in study
  • Current chronic illness that involves constant or frequent pain if their acute pain complaint at ED presentation is not due to the chronic illness. (case-by-case basis)
  • Current chronic pain from various sources if their acute pain complaint at ED presentation is not related to their current chronic pain. (case-by-case basis)

Критерии исключения

  • Pain intensity great enough to impair concentration or capacity to understand instructions or the nature of being invited into a study as assessed by a member of the medical staff
  • Any injury or illness that precludes their ability to understand or follow instructions as assessed by a member of the medical staff
  • Self-reported history of chronic pain on presentation to the ED or documented in the electronic medical record (case-by-case basis)
  • Pain from traumatic event that is the source of their PTSD
  • Neurological disorder
  • Blood pressure greater than 160/100 mmHg
  • Taking anticoagulants or antiplatelet drugs other than aspirin
  • Pregnancy
  • Current alcohol or substance dependence
  • Anything that precludes interventions from being successful.
  • We will exclude people who are being treated for chronic or significant diseases such as rheumatoid disease, current influenza that may manifest temporary flu- related pain, and heart disease.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

США · 1 центр
  • Rush University Medical Center — Chicago

Идентификаторы

NCT: NCT05700279 · 21092002

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗